Clinical trials: Depression / Major Depressive Disorder
Depressive Disorder, Major
A Study of LY2216684 in Participants With Impaired Hepatic Function
The purpose of this study is to evaluate the effect of liver function on how much of the study drug (LY2216684) gets into the blood stream and how long it takes the body to get rid of it.
- Trial name
- NCT01241435
- Testing
- LY2216684
- Where
- 3 sites in United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD) who are taking certain types of antidepressants but continue to have residual depression symptoms.
- Trial name
- NCT01436149
- Testing
- SPD489 (Lisdexamfetamine dimesylate )
- Where
- 85 sites in United States, Canada and 4 more
- Volunteers
- 1,262 people
- Sponsor
- Shire
Post Traumatic Stress Disorder, Major Depressive Disorder
Antidepressant Response in Older Adults With Comorbid PTSD and MDD
In the Investigator's ongoing studies of Posttraumatic Stress Disorder (PTSD) in older adults, it has been found that older adults with PTSD frequently meet the criteria for comorbid Major Depressive Disorder (MDD).
- Trial name
- NCT04697693
- Testing
- Escitalopram, Duloxetine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder
Ketamine in Adolescents With Treatment-Resistant Depression
This study will test the use of ketamine for treatment of depression in adolescents that have not responded to other treatments. We will also examine neurobiological mechanisms of treatment.
- Trial name
- NCT02078817
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Minnesota
Depressive Disorder, Major
A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine
This study is open to adults between 18 and 65 with a type of depression (major depressive disorder) for whom previous treatments for depression did not work.
- Trial name
- NCT06280235
- Testing
- BI 1569912
- Where
- 52 sites in United States, Belgium and 5 more
- Volunteers
- 243 people
- Sponsor
- Boehringer Ingelheim
Treatment Outcome
Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction
The purpose of this study is to evaluate the effects of Vortioxetine (Lu AA21004), once daily (QD), compared with escitalopram on sexual functioning.
- Trial name
- NCT01364649
- Testing
- Vortioxetine, Escitalopram
- Where
- 62 sites in United States, Canada
- Volunteers
- 447 people
- Sponsor
- Takeda
Major Depressive Disorder
Transcranial Magnetic Stimulation for Adolescent Depression
Major depression (or MDD) in adolescents is a major public health problem. MDD affects approximately 15% of adolescents; it is associated with impairment in social, family, and academic functioning, and it is a major risk factor…
- Trial name
- TMSAD (NCT01731678)
- Testing
- Transcranial Magnetic Stimulation
- Where
- Canada
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- University of Calgary
Major Depression
Antidepressant Effects of NR2B in Major Depression
Purpose : This study will determine whether MK-0657, a selective NR2B Antagonist, can quickly improve symptoms of depressed mood, psychomotor retardation, poor motivation and reduced enjoyment of things in patients with major…
- Trial name
- NCT00472576
- Testing
- MK-0657
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Institute of Mental Health (NIMH)
Major Depression, Epilepsy
Lexapro for Major Depression in Patients With Epilepsy
The primary objective will be to pilot the use of escitalopram for the treatment of major depression in patients with epilepsy. The secondary objectives will be to determine effect sizes on scales measuring depressive symptoms…
- Trial name
- NCT01244724
- Testing
- Lexapro
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Weill Medical College of Cornell University
Major Depressive Disorder, Alcohol Use Disorder
STAR*D Alcohol: Treatment of Depression Concurrent With Alcohol Abuse
The purpose of this study is to determine if having an alcohol use disorder affects recovery from depression, and also whether recovery from depression in patients who have alcohol use disorders is also accompanied by improvement…
- Trial name
- NCT00369746
- Testing
- citalopram
- Where
- United States
- Volunteers
- 674 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder
Safety and Effectiveness of NeuroStar® Transcranial Magnetic Stimulation (TMS) Therapy in Depressed Adolescents
To evaluate the safety and efficacy of daily, active Neurostar® TMS (when compared with sham treatment) in adolescents meeting criteria for Major Depressive Disorder (MDD).
- Trial name
- NCT02586688
- Testing
- Active NeuroStar® Transcranial Magnetic Stimulation (TMS)
- Where
- 13 sites in United States
- Volunteers
- 112 people
- Sponsor
- Neuronetics
Major Depressive Disorder
A Study to Measure if There is Any Difference in How the Body Breaks Down or Inactivates Either Fluoxetine or LY2216684 When Both of These Medicines Are Given Together.
The purpose of this study is to measure if there is any difference in how the body breaks down or inactivates either fluoxetine or LY2216684 when both of these medicines are given together.
- Trial name
- NCT01243957
- Testing
- LY2216684, Fluoxetine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder
The primary purpose of this study is to compare the antidepressant efficacy and safety of two doses of desvenlafaxine succinate sustained release (10 and 50 mg/day) in adults with Major Depressive Disorder.
- Trial name
- NCT00863798
- Testing
- Desvenlafaxine Succinate Sustained-Release 10mg, Desvenlafaxine Succinate Sustained-Release 50 mg
- Where
- 24 sites in United States
- Volunteers
- 682 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Depressive Disorder, Major
A Study to Evaluate the Effect of Food on LY2216684
This study will evaluate the effect of food on LY2216684. There will be 2 study periods each lasting up to 5 days. There will be at least 7 days between the two doses and a follow up will occur at least 7 days after the last…
- Trial name
- NCT01389765
- Testing
- LY2216684
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
A Study for Participants With Major Depression
This is a study to assess the safety and effectiveness of LY2216684 compared to placebo in treating adults with major depressive disorder.
- Trial name
- NCT00420004
- Testing
- LY2216684, Escitalopram
- Where
- 7 sites in United States, Romania
- Volunteers
- 469 people
- Sponsor
- Eli Lilly and Company
Depression
Adding an Insulin-Sensitizing Medication to Depression Treatment for People Who Are Depressed and Overweight
This study will determine whether the drug metformin improves the effects of traditional antidepressant medications in people who are overweight.
- Trial name
- NCT00834652
- Testing
- Sertraline, Metformin
- Where
- United States
- Volunteers
- 206 people
- Sponsor
- Washington University School of Medicine
Older Adults, Anxiety
Behavioral Activation and Medication Optimization For Improving Perioperative Mental Health In Older Adults Undergoing Oncologic Surgery
Using a Hybrid Type 1 Effectiveness-Implementation randomized control trial (RCT) design, the investigators will test the effectiveness of a bundled behavioral activation and medication optimization in reducing symptoms of…
- Conditions
- Older Adults, Anxiety, Depression, Major Surgical Resection of a Thoracic Malignancy
- Trial name
- NCT05685511
- Testing
- Behavioral Activation, Medication Optimization, Usual care resources
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- Washington University School of Medicine
Depression, Opioid-use Disorder
Ketamine for the Treatment of Opioid Use Disorder and Depression
The purpose of the study is to examine whether an investigational medication called ketamine is able to improve treatment outcomes for concurrent opioid addiction and depression when used in conjunction with buprenorphine…
- Conditions
- Depression, Opioid-use Disorder, Opioid Abuse
- Trial name
- NCT04177706
- Testing
- Ketamine Hydrochloride
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Medical University of South Carolina
Major Depressive Disorder
Pilot Study of Duloxetine in Psychological Resilience
The purpose of this study is to explore benefits of duloxetine in enhancing psychological resilience and to understand the relevance of inhibiting of both serotonin (5HT) and norepinephrine (NE)to therapeutic responses.
- Trial name
- NCT00331799
- Testing
- Duloxetine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Duke University
Major Depressive Disorder
iCBT With TMS in Patients With MDD
Major Depressive Disorder (MDD) is a common mental health diagnosis. While there are many approaches to the treatment of MDD, current treatments of MDD often do not substantially reduce depressive symptoms among those in need of…
- Trial name
- NCT05988619
- Testing
- Transcranial Magnetic Stimulation, Internet-Based Cognitive Behavioral Therapy, Psychoeducation
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of California, Los Angeles